Table 2. Risk of adverse kidney outcomes according to RC levels.
| RC | Number | Event (%) | Duration (PY) | IR (/1,000 PY) | Model 1* | Model 2† | Model 3‡ | Model 4§ | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | ||||||
| KRT initiation | |||||||||||||
| Q1 | 522 | 124 (24) | 3,337 | 37.2 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | |||||
| Q2 | 522 | 141 (27) | 3,265 | 43.2 | 1.16 (0.91–1.48) | 0.227 | 1.13 (0.89–1.44) | 0.305 | 1.22 (0.95–1.57) | 0.123 | 1.21 (0.94–1.56) | 0.135 | |
| Q3 | 522 | 181 (35) | 2,996 | 60.4 | 1.64 (1.30–2.06) | <0.001 | 1.60 (1.27–2.01) | <0.001 | 1.32 (1.03–1.70) | 0.026 | 1.32 (1.03–1.70) | 0.026 | |
| Q4 | 521 | 208 (40) | 2,797 | 74.4 | 2.02 (1.62–2.52) | <0.001 | 1.96 (1.57–2.46) | <0.001 | 1.42 (1.07–1.89) | 0.015 | 1.40 (1.06–1.86) | 0.020 | |
| RC per 1–SD increase | 1.22 (1.16–1.29) | <0.001 | 1.22 (1.15–1.29) | <0.001 | 1.16 (1.05–1.29) | 0.003 | 1.16 (1.05–1.29) | 0.004 | |||||
| Composite kidney event | |||||||||||||
| Q1 | 522 | 177 (34) | 3,149 | 56.2 | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | 1.00 (Reference) | |||||
| Q2 | 522 | 189 (36) | 3,081 | 61.3 | 1.09 (0.89–1.34) | 0.395 | 1.08 (0.88–1.32) | 0.468 | 1.03 (0.84–1.28) | 0.754 | 1.03 (0.83–1.27) | 0.806 | |
| Q3 | 522 | 227 (43) | 2,790 | 81.4 | 1.46 (1.20–1.78) | <0.001 | 1.43 (1.18–1.74) | <0.001 | 1.12 (0.91–1.39) | 0.283 | 1.12 (0.91–1.39) | 0.291 | |
| Q4 | 521 | 257 (49) | 2,585 | 99.4 | 1.80 (1.48–2.17) | <0.001 | 1.76 (1.46–2.14) | <0.001 | 1.25 (0.98–1.60) | 0.076 | 1.23 (0.96–1.58) | 0.095 | |
| RC per 1–SD increase | 1.20 (1.14–1.26) | <0.001 | 1.20 (1.14–1.26) | <0.001 | 1.14 (1.04–1.25) | 0.004 | 1.14 (1.04–1.25) | 0.004 | |||||
PY, person-years; IR, incidence rate; HR, hazard ratio; CI, confidence interval; KRT, kidney replacement therapy; SD, standard deviation; RC, remnant cholesterol.
*Model 1 is unadjusted.
† Model 2 is adjusted for age and sex.
‡ Model 3 is adjusted for age, sex, smoking status, diabetes mellitus, hypertension, body mass index, angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, statin use, fibrate use, stage of chronic kidney disease, and baseline levels of low-density lipoprotein cholesterol, high-density lipoprotein cholesterol, and triglycerides.
§ Model 4 is further adjusted for statin intensity.